The WHO Research & Development Blueprint
In 2015, at the request of 194 member states, the World Health Organization brought together a broad coalition of experts to develop the Research and Development Blueprint for priority emerging infectious diseases. The blueprint comprises an evolving list of emerging diseases that pose a severe public health risk with epidemic potential, and for which insufficient, or no preventive and curative solutions currently exist.
The diseases listed pose a major risk to global public health and play a central role in antibiotic resistance, food insecurity and the global economy. In response, the WHO has urged for accelerated development of vaccines and the increased availability of accurate and reliable diagnostics.
At The Native Antigen Company, the WHO R&D Blueprint is paramount in guiding our efforts to support ongoing research into the prevention and diagnosis of endemic and emerging diseases.
Our mission is to reduce the global burden of infectious disease by developing the highest-quality viral, bacterial and protozoal reagents in rapid response to emerging public health threats.
We strive to maintain strong relationships with industry and academia to ensure a truly excellent service. Our antigens are used by leading pharmaceutical companies and IVD manufacturers in cutting-edge vaccine and serology research, where our highly pure and reliable products are crucial to effective R&D.
In addition to our rapidly expanding portfolio of antigens, we are now developing a range of highly-specific antibodies and ELISA immunoassays for the development of novel diagnostics and vaccines.
Ethical & Sustainable
We are proud of the fact that all of our electricity is from 100% supplied by Ecotricity as renewable sources. They even provide us with a certificate to confirm these credentials.
All of our packaging is recyclable, so please consider the environment when unpacking your deliveries from us!